ANALYSIS OF THE MECHANISM OF ACTION OF THE GALEGA OFFICINALIS L

DOI: https://doi.org/10.29296/25877313-2019-09-02
Issue: 
9
Year: 
2019

I.A. Martinchik Research Scientist, All-Russian Research Scientific Institute of Medicinal and Aromatic Herbs (Moscow) E-mail: Iruna-martynchik@mail.ru T.E. Trumpe Ph.D. (Biol.) Leading Research Scientist, All-Russian Research Scientific Institute of Medicinal and Aromatic Plants (Moscow) E.V. Ferubko Ph.D. (Med.), All-Russian Research Scientific Institute of Medicinal and Aromatic Plants (Moscow)

Galega medicinal (Galega officinalis L.) is a perspective medicinal plant of antidiabetic action. Positive influence of a galega on various links of pathological process at a diabetes mellitus is explained by the maintenance of a complex of biologically active agents, one of which is guanidinovy al-kaloid galegine (izoamilen-guadin). Galegine can work like guanyl guanidines - group of synthetic glucose-lowering drugs, for example as Metforminum, the patients with a diabetes mellitus who are applied to treatment. The similarity of pharmacological activity of galegine and metformin is caused by proximity of chemical composition and respectively proximity of mechanisms of effect of the specified substances. According to literary data an im-portant target of Metforminum is adenosinemonophosphate - the activated protein kinase (AMFK) - the key regulator of power metabolism of a cell. Ac-tivation of AMFK leads to reduction of endothelial dysfunction, easing of an oxidative stress, improvement of utilization of glucose and increase in bio-logical activity of insulin. Such metabolic activity does this enzyme by one of major factors of protection of a cardiovascular system in the conditions of a diabetes mellitus and can explain various effects of guanyl guanidines. Also the LKB1/AMFK mechanism provides molecular interrelation between a diabetes mellitus and cancer. Metforminum reduces metabolic defect and restored generation of T-memory cells. The mechanism of effect of met-formin and a galega medicinal opens a wide range of their pharmacological action.

Keywords: 
galegalekarstvenny
alkaloid galegine
metformin
diabetes mellitus
antidiabetic means
guanyl guanidine

References: 
  1. Yakimova T.V., Nasanova O.N., Vengerovskij A.I., Burkova V.N. Vliyanie ekstrakta galegi lekarstvennoj na metabolizm lipidov pri eksperimental'nom saharnom dia-bete // Sibirskij medicinskij zhurnal. 2011. T. 26. № 4. Vyp. 2. S. 98102.
  2. Palej A.E., Logvinenko I.E., Logvinenko L.A., Grebennikova O.A., Vinogradov B.A. Biologicheski aktivnye veshchestva galegi lekarstvennoj (Gallega officinalis L.) // Trudy Nikitskogo botanicheskogo sada. Nikitinskij botanicheskij sad – Nacional'nyj nauchnyj centr. 2011. T. 133. S. 152159.
  3. Chekina N.A., Chukaev S.A., Nikolaev S.M. Saharnyj diabet: vozmozhnosti farmakoterapii s ispol'zovaniem sredstv rastitel'nogo proiskhozhdeniya // Vestnik BGU. 2010. № 12. S. 7178.
  4. Trumpe T.E. Fitoterapiya saharnogo diabeta // V kn.: «Aktual'nye voprosy fitoterapii». Materialy yubilejnoj konferencii ROO «Fitoterapevticheskoe obshchestvo». 2002. S. 124127.
  5. Kravchuk E.N., Galagudza M.M. Primenenie metformina pri sochetanii ishemicheskoj bolezni serdca i saharnogo diabeta 2 tipa: mekhanizmy dejstviya i klinich-eskaya effektivnost'. // Saharnyj diabet. 2013. № 1. S. 514.
  6. Smirnova O.M. Mesto metformina v sovremennom lechenii i profilaktike saharnogo diabeta 2 tipa // Saharnyj diabet. 2010. № 3. S. 514.
  7. Martynchik I.A., Trumpe T.E. Galega lekarstvennaya (Galega officinalis L.) – perspektivnoe rastenie gipoglikemicheskogo dejstviya (obzor literatury) // Sb. trudov Mezhdunar. nauch. konf. «Perspektivy lekarstvennogo rastenievedeniya». M. 2018. S. 679683.
  8. Demidova I.Yu., Gorohova T.V. Mekhanizm dejstviya i klinicheskoe primenenie metformina (siofor): obzor literatury // Farmateka. 2009. № 9. S. 1015.
  9. Demidova I.Yu., Drozdova I.N. Metformin: novye preimushchestva v svete dokazatel'noj mediciny // Effektivnaya farmakoterapiya. 2015. № 28. S. 3236.
  10. Starostina E.G. Mesto metformina v terapii SD 2-go tipa. // http://www.voed.ru/art_029.htm
  11. Bueverov A.O. Bezopasnost' metformina s tochki zreniya gepatologa // Ozhirenie i metabolizm. 2010. № 2. S. 7376.
  12. Bowker S.L., Majumdar S. R., Veugelers P., et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin // Diabetes Care. 2006. № 29. Р. 254258.
  13. Evans J. M., Donnelly L.A., Emslie-Smith A.M., Alessi D.R., Morris A.D. Metformin and reduced risk of cancer of 2537% in diabetic patients // BMJ. 2005. № 330. Р. 13041305.
  14. Monami M., Colombi C., Balzi D., et al. Metformin and cancer occurrence in insulin-treated type 2 diabetic patients // Diabetes Care January. 2011.
  15. № 34. Р. 129131.
  16. Strelkova L.B., Kondakova I.V., Dubinskaya V.A., Bykov V.A. Inducibel'naya NO-sintaza kak fermentnaya biotest-sistema dlya vyyavleniya veshchestv s pro-tivovospalitel'nymi svojstvami in vitro // Voprosy biologicheskoj, medicinskoj i farmacevticheskoj himii. 2013. № 11. S. 7580.
  17. Kutovaya A.M., Davydova V.N. Galega lekarstvennaya kak perspektivnoe rastenie v HKHI veke // Sb. trudov 3-ej nauchno-praktich. konf. aspirantov i molodyh uchenyh «Molodye uchenye i farmaciya HKHI veka». M. 2015. S. 8284.
  18. Tizina N.G. Galega vostochnaya i lekarstvennaya // Sb. nauchnyh trudov VILAR «Geneticheskie resursy lekarstvennyh i aromaticheskih rastenij». Materialy mezhdunarodnoj konferencii. M. 2004. S. 318320.